Skip to main content
. 2021 Aug 31:1–12. doi: 10.1080/07391102.2021.1969281

Figure 2.

Figure 2.

Three dimensional (left) and schematic representations (right) of (a) chondramide C3 (1) against wild-type, (b) chondramide C (2) against N501Y, and (c) chondramide C (2) against E484K SARS-CoV-2 spike variants.